Paediatric safety signals identified in VigiBase: Methods and results from Uppsala Monitoring Centre
Authors:
Open Access
- 15 February 2019
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 28 (5) , 680-689
Abstract
Purpose The purpose of this study is to uncover previously unrecognised risks of medicines in paediatric pharmacovigilance reports and thereby advance a safer use of medicines in paediatrics. Methods Individual case safety reports (ICSRs) with ages less than 18 years were retrieved from VigiBase, the World Health Organization (WHO) global database of ICSRs, in September 2014. The reports were grouped according to the following age spans: 0 to 27 days; 28 days to 23 months; 2 to 11 years; and 12 to 17 years. vigiRank, a data‐driven predictive model for emerging safety signals, was used to prioritise the list of drug events by age groups. The list was manually assessed, and potential signals were identified to undergo in‐depth assessment to determine whether a signal should be communicated. Results A total of 472 drug‐event pairs by paediatric age groups were the subject of an initial manual assessment. Twenty‐seven drug events from the two older age groups were classified as potential signals. An in‐depth assessment resulted in eight signals, of which one concerned harm in connection with off‐label use of dextromethorphan and another with accidental overdose of olanzapine by young children, and the remaining signals referred to potentially new causal associations for atomoxetine (two signals), temozolamide, deferasirox, levetiracetam, and desloratadine that could be relevant also for adults. Conclusions Clinically relevant signals were uncovered in VigiBase by using vigiRank applied to paediatric age groups. Further refinement of the methodology is needed to identify signals in reports with ages under 2 years and to capture signals specific to the paediatric population as a risk group.Keywords
This publication has 21 references indexed in Scilit:
- Pharmacovigilance for Children’s SakeDrug Safety, 2014
- Systematic review of safety in paediatric drug trials published in 2007European Journal of Clinical Pharmacology, 2011
- Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discoveryStatistical Methods in Medical Research, 2011
- Suspected Adverse Drug Reactions Reported For Children WorldwideDrug Safety, 2011
- Low quality of reporting adverse drug reactions in paediatric randomised controlled trialsArchives of Disease in Childhood, 2010
- A systematic review of safety monitoring and drug toxicity in published randomised controlled trials of antiepileptic drugs in children over a 10-year periodArchives of Disease in Childhood, 2010
- Defining ‘Signal’ and its Subtypes in Pharmacovigilance Based on a Systematic Review of Previous DefinitionsDrug Safety, 2009
- Duplicate detection in adverse drug reaction surveillanceData Mining and Knowledge Discovery, 2007
- Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring DatabasePharmacoepidemiology and Drug Safety, 2004
- Principles of Signal Detection in PharmacovigilanceDrug Safety, 1997